about
Rescue of recent virulent and avirulent field strains of bluetongue virus by reverse geneticsBluetongue viruses based on modified-live vaccine serotype 6 with exchanged outer shell proteins confer full protection in sheep against virulent BTV8Current and next-generation bluetongue vaccines: Requirements, strategies, and prospects for different field situations.A cross-sectional study to determine the seroprevalence of bluetongue virus serotype 8 in sheep and goats in 2006 and 2007 in the Netherlands.Full genome characterisation of bluetongue virus serotype 6 from the Netherlands 2008 and comparison to other field and vaccine strains.Potential role of ticks as vectors of bluetongue virus.Immunogenicity of recombinant VP2 proteins of all nine serotypes of African horse sickness virus.Virus and host factors affecting the clinical outcome of bluetongue virus infection.RNA elements in open reading frames of the bluetongue virus genome are essential for virus replicationBluetongue, Schmallenberg - what is next? Culicoides-borne viral diseases in the 21st Century.Non-structural protein NS3/NS3a is required for propagation of bluetongue virus in Culicoides sonorensis.Rapid generation of replication-deficient monovalent and multivalent vaccines for bluetongue virus: protection against virulent virus challenge in cattle and sheepReplication-Deficient Particles: New Insights into the Next Generation of Bluetongue Virus Vaccines.Validation of a commercial ELISA for the detection of bluetongue virus (BTV)-specific antibodies in individual milk samples of Dutch dairy cows.A Review of Knowledge Gaps and Tools for Orbivirus Research.Experimental infection of small ruminants with bluetongue virus expressing Toggenburg Orbivirus proteins.Balance of RNA sequence requirement and NS3/NS3a expression of segment 10 of orbiviruses.VP2 Exchange and NS3/NS3a Deletion in African Horse Sickness Virus (AHSV) in Development of Disabled Infectious Single Animal Vaccine Candidates for AHSV.Viral replication kinetics and in vitro cytopathogenicity of parental and reassortant strains of bluetongue virus serotype 1, 6 and 8.European Bluetongue Serotype 8: Disease Threat Assessment for U.S. Sheep.Bluetongue virus without NS3/NS3a expression is not virulent and protects against virulent bluetongue virus challenge.Bluetongue virus nonstructural protein NS3/NS3a is not essential for virus replication.Bluetongue virus with mutated genome segment 10 to differentiate infected from vaccinated animals: a genetic DIVA approach.Sequence analysis of bluetongue virus serotype 8 from the Netherlands 2006 and comparison to other European strains.Preliminary mapping of non-conserved epitopes on envelope glycoprotein E2 of Bovine viral diarrhea virus type 1 and 2.Sustained high-throughput polymerase chain reaction diagnostics during the European epidemic of Bluetongue virus serotype 8.Bluetongue Disabled Infectious Single Animal (DISA) vaccine: Studies on the optimal route and dose in sheep.A common neutralizing epitope on envelope glycoprotein E2 of different pestiviruses: implications for improvement of vaccines and diagnostics for classical swine fever (CSF)?Structural Protein VP2 of African Horse Sickness Virus Is Not Essential for Virus Replication In Vitro.Development of a competitive ELISA for NS3 antibodies as DIVA test accompanying the novel Disabled Infectious Single Animal (DISA) vaccine for Bluetongue.Experimental non-transmissible marker vaccines for classical swine fever (CSF) by trans-complementation of E(rns) or E2 of CSFV.Requirements and comparative analysis of reverse genetics for bluetongue virus (BTV) and African horse sickness virus (AHSV).The major envelope protein, GP5, of a European porcine reproductive and respiratory syndrome virus contains a neutralization epitope in its N-terminal ectodomain.Safety and protective efficacy of porcine reproductive and respiratory syndrome recombinant virus vaccines in young pigs.Recovery of infectious classical swine fever virus (CSFV) from full-length genomic cDNA clones by a swine kidney cell line expressing bacteriophage T7 RNA polymerase.Application of bluetongue Disabled Infectious Single Animal (DISA) vaccine for different serotypes by VP2 exchange or incorporation of chimeric VP2.VP2-serotyped live-attenuated bluetongue virus without NS3/NS3a expression provides serotype-specific protection and enables DIVA.Genetic modification of Bluetongue virus by uptake of "synthetic" genome segments.High-level expression of biologically active recombinant bovine follicle stimulating hormone in a baculovirus system.Experimental infection of white-tailed deer (Odocoileus virginianus) with Northern European bluetongue virus serotype 8.
P50
Q27309749-30719311-945A-468B-A8E4-963F6714F1E3Q27319898-51E83D67-0437-42FB-9BA7-57C8159CA9F7Q30242080-6A692C26-59DA-409A-9F15-DC957C0684E5Q33364288-4CA4C9E6-7657-423E-A58A-03672A183B1CQ33567674-CB70048C-E18F-4EF5-BD83-7DF1F4C2D79BQ33567674-ED36948A-2D30-4B76-85C3-44DEF1CDE472Q34086755-09B3E73B-02BC-42AB-ADA8-A2D729C51A30Q34106625-5A1CD9A6-0EF7-4D8A-A461-22DA279F0C90Q34262237-2E24A780-E6E0-49A1-9BF7-4BBAAA7F34D9Q35128134-3AF57BA8-C337-4842-B218-95373660BCA3Q35135742-E04B50C9-3A04-4E87-B049-BF62386650CDQ36070650-59F7D9F1-9553-4A08-BE0C-D9E12C32F2CCQ37123514-2F2D12CB-A1B3-4840-A0D3-31341AF10D2DQ37512822-CE820880-1A66-41B3-ABDE-8E00D7EE7841Q38477671-68781B96-8BE2-4B41-9F43-10158428E1A0Q38530944-D1BE4EE5-3962-43F7-88C2-BD00B517041EQ38751656-EDF96FF9-C1B7-41D6-8305-73CD14D8EA29Q38813822-2ACB2791-6323-4C3C-923E-F3B78D8FE0CEQ38865167-5EBEF11C-5458-4C54-A016-C4BD5C98075EQ38949724-64438FC9-31EE-4E33-B776-15DE6EA128E2Q38978186-7669DC65-F78B-452A-BF36-04C688EC6F38Q38986302-30935051-A072-4CB1-90BD-75B12BBA28D8Q39030331-C5ECD2A8-6C99-4481-9694-BAD6D88C4B5DQ39097821-39098B69-9B70-44E6-BEA6-CA432AB05103Q39198648-F6779882-7460-4866-9C04-7FFFC5C5326BQ40241814-1BAE8979-BA73-47F3-8CAF-2348CE2B8D1FQ40289313-ED2F6CF5-046E-424D-BAA1-FADA8F46C4DEQ40424507-5F9B5E5A-C1E0-4B7C-B0BB-891185840244Q40447606-FCA196CD-0A38-4C54-AE8B-069D44E08C6FQ40448117-5050BFE7-78A0-4021-96F4-18B5252787E6Q40521519-D195D51F-95F8-4E41-AEC4-819165DDCA7AQ40587942-44972486-7A8A-4D88-BA62-A5806B2E2C14Q40628405-15E0C643-9CC8-4933-B781-3BA561DAF85EQ40644350-3631DD45-6DD6-4C27-86AE-4D73E42B868EQ40648199-B38302DE-562B-4C17-83F6-30FEC352964CQ40817409-ED95B1CA-48A8-4C32-BD99-D4D73F0ED5D4Q41598123-05419B4D-4984-4BBA-AF97-912B8B99A905Q41630567-D319FE8D-6A0C-4829-B72E-82CC6ED13751Q41817570-A43EE38D-DDA6-4712-908B-5C55BAE5FAB0Q42061016-DAB794AA-BF8D-45E6-A4E8-DB690F0BDE75
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Piet A van Rijn
@ast
Piet A van Rijn
@en
Piet A van Rijn
@es
Piet A van Rijn
@sl
type
label
Piet A van Rijn
@ast
Piet A van Rijn
@en
Piet A van Rijn
@es
Piet A van Rijn
@sl
prefLabel
Piet A van Rijn
@ast
Piet A van Rijn
@en
Piet A van Rijn
@es
Piet A van Rijn
@sl
P108
P1053
C-1163-2017
P106
P108
P1153
7003818933
P21
P31
P3829
P496
0000-0002-2594-1232